RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat myeloma: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug, linvoseltamab, alone or with another drug called carfilzomib, against standard treatments for people with multiple myeloma that has returned or not responded to prior therapy. About 915 participants who have had 1 to 3 prior treatments will be enrolle…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New scan could spot hidden myeloma earlier
Diagnosis Recruiting nowThis phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant w…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jul 02, 2026 00:00 UTC